Get started
Author

Shanshan Suo

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy
2015 · Yinjun Lou, Yafang Ma, et al. · Leukemia Research · 48
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells
2017 · Jian Chen, Qitian Mu, et al. · Oncotarget · 33
PDF
K lf10 inhibits IL ‐12p40 production in macrophage colony‐stimulating factor‐induced mouse bone marrow‐derived macrophages
2012 · Wei Zhang, Xuelian Wang, et al. · European Journal of Immunology · 29
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study
2023 · Yi Zhang, Hu Zhou, et al. · American Journal of Hematology · 26
PDF
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy
2013 · Yinjun Lou, Shanshan Suo, et al. · Leukemia Research · 25
RARγ-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen
2019 · Xiang Zhang, Fenglin Li, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia
2014 · Jie Jin, Jian Chen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b
2024 · Shanshan Suo, Rong Feng Fu, et al. · British Journal of Haematology · 18
PDF
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia
2024 · Shanshan Suo, Dandan Zhao, et al. · Blood · 17
PDF
Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy
2014 · Yinjun Lou, Shanshan Suo, et al. · Annals of Hematology · 16
Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed
2024 · Shanshan Suo, Shu Sun, et al. · Med · 15
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single‐arm , open‐label , phase 2, multicenter study
2023 · Yi Zhang, Qike Zhang, et al. · American Journal of Hematology · 15
PDF
Improved long‐term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide‐based front‐line therapy
2018 · Yinjun Lou, Ying Lu, et al. · Hematological Oncology · 12
miR-221-3p Delivered by BMMSC-Derived Microvesicles Promotes the Development of Acute Myelocytic Leukemia
2020 · Xuewu Zhang, Yu Xu, et al. · Frontiers in Bioengineering and Biotechnology · 11
PDF
Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study
2020 · Yi Zhang, Shan-Shan Suo, et al. · Journal of Cancer Research and Clinical Oncology · 11
PDF
Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera
2025 · Albert Qin, Kazuya Shimoda, et al. · Pharmacology Research & Perspectives · 10
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
2021 · Junjing Qiao, Chen Liang, et al. · Leukemia · 10
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002 : A phase 2 study comparing jaktinib at 100 mg twice daily ( BID ) and 200 mg once daily ( QD ) in patients with myelofibrosis
2024 · Yi Zhang, Hu Zhou, et al. · American Journal of Hematology · 8
PDF
Hypofibrinogenemia as a clue in the presumptive diagnosis of acute promyelocytic leukemia
2016 · Yinjun Lou, Shanshan Suo, et al. · Leukemia Research · 8
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
2024 · Yi Zhang, Hu Zhou, et al. · Blood Cancer Journal · 7
PDF
Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia
2024 · Keita Kirito, Albert Qin, et al. · BJC Reports · 7
PDF
Acute myocardial/cerebral infarction as first/relapse manifestation in one acute promyelocytic leukemia patient.
2015 · Ying Li, Shanshan Suo, et al. · PubMed · 6
Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development By Recruiting SHP2
2021 · Shanshan Suo, Le Xuan Truong Nguyen, et al. · Blood · 5
Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients
2020 · Shan-shan Suo, Chen-ying Li, et al. · Journal of Zhejiang University SCIENCE B · 5
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
2016 · Cuihua Fan, Wenjuan Yu, et al. · PubMed · 5
Works count: 53
Citation count: 413
H-index: 12
I10-index: 17
Year
Topic
Type